Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
SUTRO BIOPHARMA, INC. (STRO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 - - Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to an additional $250 million in milestone payments upon the achievement of certain return thresholds - - As of June 30, 2023, Sutro had cash and investments of $358.3 million and shares ..."
05/15/2023 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones - Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as an oral presentation at ASCO 2023 - - As presented at AACR 2023, STRO-003 demonstrated potent anti-tumor activity and immune-modulating properties in preclinical models, suggesting its potential to augment checkpoint blockade therapy - - As of March 31, 2023, Sutro had cash and investments of $251.5 million and shares of Vaxcyte common stock valued at $25.0 million, which together provide a projected cash runway into the second half of 2024-"
11/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones - Cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023 - - Meetings with regulatory agencies for STRO-002 are planned for mid-year 2022 and near-final dose expansion data are expected in the second half of 2022 - - First patient was dosed in the STRO-002 bevacizumab combination trial and the endometrial cohort continues to enroll patients - SOUTH SAN FRANCISCO, Calif., May 9, 2022 – Sutro Biopharma, Inc. , a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer t..."
02/28/2022 8-K Quarterly results
Docs: "Sutro Biopharma, Inc. Selected Statements of Operations Financial Data"
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones",
"Company Overview Presentation"
05/07/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments - KOL Discussion of STRO-002 Data Event scheduled for December 3rd"
08/06/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2020 Financial Results and Recent Business Highlights and Developments"
03/16/2020 8-K Quarterly results
11/08/2019 8-K Quarterly results
Docs: "Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments"
08/14/2019 8-K Quarterly results
Docs: "Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments"
05/15/2019 8-K Quarterly results
Docs: "Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments"
04/01/2019 8-K Quarterly results
Docs: "Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy